Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

被引:318
|
作者
Muranen, Taru [1 ]
Selfors, Laura M. [1 ]
Worster, Devin T. [1 ]
Iwanicki, Marcin P. [1 ]
Song, Loling [1 ]
Morales, Fabiana C. [2 ]
Gao, Sizhen [1 ]
Mills, Gordon B. [2 ]
Brugge, Joan S. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA
基金
芬兰科学院;
关键词
CAP-INDEPENDENT TRANSLATION; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; INSULIN-RECEPTOR; AKT ACTIVATION; UP-REGULATION; PI3K PATHWAY; BREAST; INITIATION; APOPTOSIS;
D O I
10.1016/j.ccr.2011.12.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including BcI-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 50 条
  • [21] PI3K inhibition to overcome endocrine resistance in breast cancer
    Keegan, Niamh M.
    Gleeson, Jack P.
    Hennessy, Bryan T.
    Morris, Patrick G.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 1 - 15
  • [22] Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?
    Ouissam, Al Jarroudi
    Hind, Chibani
    Aziz, Brahmi Sami
    Said, Afqir
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [23] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    S-U Woo
    T Sangai
    A Akcakanat
    H Chen
    C Wei
    F Meric-Bernstam
    Oncogenesis, 2017, 6 : e385 - e385
  • [24] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    Woo, S-U
    Sangai, T.
    Akcakanat, A.
    Chen, H.
    Wei, C.
    Meric-Bernstam, F.
    ONCOGENESIS, 2017, 6 : e385 - e385
  • [25] PI3K/Akt/mTOR signaling pathway in cancer stem cells
    Fath, Mohsen Karami
    Ebrahimi, Menooa
    Nourbakhsh, Ehsan
    Hazara, Ahmad Zia
    Mirzaei, Ali
    Shafieyari, Saba
    Salehi, Azadeh
    Hoseinzadeh, Mahsa
    Payandeh, Zahra
    Barati, Ghasem
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
  • [26] A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells
    Aguilar-Valdes, Alain
    Gonzalez-Vela, Francisco
    Sanchez-Vidal, Hilda
    Martinez-Aguilar, Juan
    PROTEOMICS, 2023, 23 (16)
  • [27] Mechanisms of secondary resistance to dual PI3K/mTOR inhibition in sarcomas with complex genetics
    Fourneaux, Benjamin
    Bourdon, Aurelien
    Chaire, Vanessa
    Lucchesi, Carlo
    Karanian, Marie
    Pineau, Raphael
    Laroche, Audrey
    Italiano, Antoine
    CANCER RESEARCH, 2017, 77
  • [28] Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC
    Moore, G.
    Heavey, S.
    O'Byrne, K.
    Cuffe, S.
    Finn, S. P.
    O'Neill, M.
    Gately, K.
    LUNG CANCER, 2018, 115 : S2 - S2
  • [29] Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
    Koh, King Xin
    Tan, Gim Hwa
    Low, Sarah Hong Hui
    Omar, Mohd Feroz Mohd
    Han, Min Ji
    Iacopetta, Barry
    Soo, Ross
    Beloueche-Babari, Mounia
    Bhattacharya, Bhaskar
    Soong, Richie
    ONCOTARGET, 2017, 8 (66) : 110133 - 110144
  • [30] Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways
    Provenzano, Aaron
    Kurian, Sobha
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (02) : 143 - 147